Table 2.
Cell cycle distribution and sub G1 DNA content after Dasatinib treatment.
| Cell line | Treatment | Days | Percent | |||
|---|---|---|---|---|---|---|
| Sub G1 | G1 | S | G2/M | |||
| HTLA-230 | Untreated | 1.6 | 35.9 | 24.1 | 38.4 | |
| Dasatinib (490 nM)* | 1 | 3.0 | 40.2 | 16.4 | 40.4 | |
| 2 | 6.4 | 36.8 | 18.6 | 38.2 | ||
| 3 | 56.9 | 24.1 | 9.4 | 9.6 | ||
| RN-GA | Untreated | 0.6 | 41.3 | 33.0 | 25.1 | |
| Dasatinib (1000 nM)** | 1 | 5.1 | 67.4 | 16.2 | 11.3 | |
| 2 | 58.4 | 32.7 | 4.9 | 4.0 | ||
| 3 | 51.6 | 43.2 | 2.5 | 2.7 | ||
| SH-EP | Untreated | 7.8 | 66.5 | 14.0 | 11.7 | |
| Dasatinib (133 nM)* | 1 | 7.6 | 69.8 | 13.2 | 9.4 | |
| 2 | 6.9 | 69.1 | 13.5 | 10.5 | ||
| 3 | 13.4 | 70.8 | 9.7 | 6.1 | ||
| SY5Y | Untreated | 11.5 | 66.9 | 7.2 | 14.4 | |
| Dasatinib (110 nM)* | 1 | 10.0 | 81.3 | 3.1 | 5.5 | |
| 2 | 13.1 | 79.4 | 1.7 | 6.1 | ||
| 3 | 23.4 | 67.0 | 2.9 | 6.7 | ||
| KCNR | Untreated | 1.0 | 63.1 | 12.4 | 23.4 | |
| Dasatinib (1000 nM)** | 1 | 7.6 | 54.2 | 13.3 | 25.0 | |
| 2 | 6.8 | 51.6 | 19.4 | 21.2 | ||
| 3 | 4.9 | 55.8 | 18.9 | 20.4 | ||
*
Dasatinib concentration equal to calculated IC50 + 20 %.
**
Maximum Dasatinib concentration used in this study.